SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-071174
Filing Date
2024-08-20
Accepted
2024-08-20 17:00:50
Documents
15
Period of Report
2024-08-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021197101-8k_estrella.htm   iXBRL 8-K 34678
2 PRESS RELEASE ISSUED BY ESTRELLA IMMUNOPHARMA, INC. ON AUGUST 14, 2024. ea021197101ex99-1_estrella.htm EX-99.1 10532
  Complete submission text file 0001213900-24-071174.txt   277034

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE esla-20240814.xsd EX-101.SCH 3874
4 XBRL DEFINITION FILE esla-20240814_def.xml EX-101.DEF 27189
5 XBRL LABEL FILE esla-20240814_lab.xml EX-101.LAB 37584
6 XBRL PRESENTATION FILE esla-20240814_pre.xml EX-101.PRE 25810
17 EXTRACTED XBRL INSTANCE DOCUMENT ea021197101-8k_estrella_htm.xml XML 6204
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

IRS No.: 861314502 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 241225988
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)